1310152

UNITED STATES OF AMERICA
BEFORE THE FEDERAL TRADE COMMISSION

I. RESPONDENT

1. Respondent Actavis is a corporation organized, existing, and doing business under and by virtue of the laws of the State of Nevada, with its corporate head office and principal place of business located at Morris Corporate Center III, 400 Interpace Parkway, Parsippany, New Jersey, 07054.

2.

d. human pharmaceutical products containing delayed-release risedronate sodium, a version of which is currently marketed under the brand name Atelvia.

6. For the purposes of this Complaint, the United States is the relevant geographic area in which to analyze the effects of the Acquisition in the relevant lines of commerce.

IV. THE STRUCTURE OF THE MARKETS

7. Warner Chilcott developed and markets the branded formulation of Femcon FE. Only Actavis and Lupin Limited ("Lupin") currently sell significant volumes of generic Femcon FE in the United States. Lupin's product is supplied by Warner Chilcott as an authorized generic version of the drug. Teva Pharmaceutical Industries Ltd. has an approved ANDA to sell generic Femcon FE, but has only *de minimis*

entry by firms for which the FDA approval process is already underway would be sufficient to prevent the competitive harm likely to result from the Acquisition.

VI. EFFECTS OF THE ACQUISITION

12. The effects of the Acquisition, if consummated, may be to substantially lessen

VII. VIOLATIONS CHARGED

13. The Transaction Agreement described in Paragraph 4 constitutes a violation of Section 5 of the FTC Act, as amended, 15 U.S.C. ' 45.

14. The Acquisition described in Paragraph 4, if consummated, would constitute a violation of Section 7 of the Clayton Act, as amended, 15 U.S.C. ' 18, and Section 5 of the FTC Act, as amended, 15 U.S.C. ' 45.

WHEREFORE, THE PREMISES CONSIDERED, the Federal Trade Commission on this twenty-seventh day of September, 2013 issues its Complaint against said Respondent.

By the Commission.

Donald S. Clark
Secretary

SEAL: